摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

2-Chloro-3-isopropyl-1,3,2-oxazaphosphorinane | 54608-29-6

中文名称
——
中文别名
——
英文名称
2-Chloro-3-isopropyl-1,3,2-oxazaphosphorinane
英文别名
2-chloro-3-isopropyl-[1,3,2]oxazaphosphinane;2-Chloro-3-(propan-2-yl)-1,3,2-oxazaphosphinane;2-chloro-3-propan-2-yl-1,3,2-oxazaphosphinane
2-Chloro-3-isopropyl-1,3,2-oxazaphosphorinane化学式
CAS
54608-29-6
化学式
C6H13ClNOP
mdl
——
分子量
181.602
InChiKey
OGDKYKHSBLDYLX-UHFFFAOYSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

计算性质

  • 辛醇/水分配系数(LogP):
    1.9
  • 重原子数:
    10
  • 可旋转键数:
    1
  • 环数:
    1.0
  • sp3杂化的碳原子比例:
    1.0
  • 拓扑面积:
    12.5
  • 氢给体数:
    0
  • 氢受体数:
    2

反应信息

  • 作为反应物:
    描述:
    2-Chloro-3-isopropyl-1,3,2-oxazaphosphorinane三正丁基氢锡 作用下, 以 为溶剂, 反应 1.0h, 以50%的产率得到3-isopropyl-2-H-1,3,2-oxaazaphosphorinane
    参考文献:
    名称:
    次磷酸的环状有机衍生物
    摘要:
    2-H-1,3,2-二恶英,二硫杂,二氮杂和氧杂氮杂膦酰基已通过还原相应的磷酰氯而制得。已经研究了这些化合物的光谱和化学性质。当研究在磷处取代的杂环的立体化学时,这些化合物被认为是系列的初始成员。对1 H,13 C和31 P NMR谱的研究表明,磷被轴向卤素,烷基,烷氧基和酰胺基取代时,会同时屏蔽4,6-C原子和对4,6进行脱屏蔽-轴向质子;将轴向Me基团引入PH片段的γ位会导致磷核共振发生30–40 ppm的高场偏移。
    DOI:
    10.1016/s0040-4020(01)98852-0
  • 作为产物:
    参考文献:
    名称:
    X-ray and proton NMR studies of the conformational equilibria of 2-Z-3-phenyl-1,3,2-oxazaphosphorinanes. Steric and stereoelectronic influences on the unexpected axial preferences of Me2N and MeNH substituents on three-coordinate phosphorus
    摘要:
    A series of 2-Z-3-phenyl-1,3,2-oxazaphosphorinanes 7-14 (Z = MeO, (CF3)2CHO, Ph, MeNH, and Me2N) containing three-coordinate phosphorus was prepared. The conformations of the six-membered rings were investigated by H-1 and P-31 NMR spectroscopy and X-ray crystallography. The rings with substituents MeO, (CF3)2CHO, Ph, and MeNH on phosphorus can be unambiguously assigned in solution to a single chair conformation with the substituent of phosphorus axial. An X-ray crystal structure of 5,5-dimethyl-2,3-diphenyl-1,3,2-oxazaphosphorinane, 11, reveals a chair form ring with the phenyl group attached axially to phosphorus. For 13 and 14 with a Me2N substituent on phosphorus, a chair-chair equilibrium (20 reversible 21) is found in solution that features an 80-90% population (DELTAG-degrees = 0.9-1.1 kcal/mol) of the Me2N axial conformation (20). This finding contrasts sharply with the known 1 kcal/mol preference for the Me2N to be equatorial in the corresponding 2-(dimethylamino)-1,3,2-dioxaphosphorinanes. The ability of the 1,3,2-oxazaphosphorinane ring to accommodate the Me2N substituent axially is also seen in the X-ray crystal of 5,5-dimethyl-3-phenyl-2-(dimethylamino)-1,3,2-oxazaphosphorinane, 13, which features a chair conformation ring that is considerably distorted compared to that of 11, quite evidently to allow the Me2N to be in the observed axial orientation, conformation 20. It is argued that the axial orientation of the Me2N in 13 and 14 is at least partly in response to steric repulsions in the alternative chair conformation 21 between the equatorial Me2N and the phenyl substituent at N(3). This effect is in direct contrast to the repulsive interactions between the N(3)Ph and axial Me2N on phosphorus previously demonstrated for four-coordinate, 2-oxo-1,3,2-oxazaphosphorinanes. The increased bond lengths within the 1,3,2-oxazaphosphorinane ring over its 1,3,2-dioxaphosphorinane counterpart (C-N vs C-O) and increased ring flexibility, along with potential n --> sigma* stereoelectronic factors of the type operative in the anomeric effect, are also proposed as potential contributors to the preferred axial orientation of Me2N in 13 and 14. The diastereomeric molecules cis- and trans-5-tert-butyl-3-phenyl-2-(dimethylamino)-1,3,2-oxazaphosphorinane, 17, also were prepared. At thermodynamic equilibrium at room temperature, cis-17 (2-Me2N and 5-t-Bu groups cis) is favored (cis/trans = 80/20). cis-17 displays a conformational equilibrium (Scheme 1) involving a chair conformer (almost-equal-to 60%) with the t-Bu equatorial and Me2N axial, cis-17a, and a single twist or boat form with both substituents pseudoequatorial, cis-17d (almost-equal-to 40%). trans-17 exists in solution in three conformations in approximately equal populations: a chair form with both t-Bu and Me2N equatorial (trans-17a) and two boat/twist forms (trans-17b and trans-17c) with the t-Bu pseudoequatorial and the Me2N pseudoaxial. The distributions of chair and boat/twist conformations can be reasonably understood in terms of the same 1,3-syn axial and vicinal PhN-(3)/Me2N(eq) steric repulsions invoked to explain the chair-chair equilibria noted for the unsubstituted and 5,5-dimethyl-2-(dimethylamino)-3-phenyl-1,3,2-oxazaphosphorinanes 13 and 14. The free energy difference between chair and boat/twist forms evidently is very small.
    DOI:
    10.1021/jo00075a018
点击查看最新优质反应信息

文献信息

  • Nifant'ev,E.E. et al., Journal of general chemistry of the USSR, 1977, vol. 47, p. 2262 - 2267
    作者:Nifant'ev,E.E. et al.
    DOI:——
    日期:——
  • Nuretdinova, O. N.; Gaidukova, N. M., Journal of general chemistry of the USSR, 1988, vol. 58, # 4, p. 676 - 680
    作者:Nuretdinova, O. N.、Gaidukova, N. M.
    DOI:——
    日期:——
  • Nifant'ev,E.E. et al., Journal of general chemistry of the USSR, 1976, vol. 46, p. 475 - 479
    作者:Nifant'ev,E.E. et al.
    DOI:——
    日期:——
  • Nifant'ev,E.E. et al., Journal of general chemistry of the USSR, 1974, vol. 44, p. 2731 - 2732
    作者:Nifant'ev,E.E. et al.
    DOI:——
    日期:——
  • NIFANTIEV, E. E.;SOROKINA, S. F.;BORISENKO, A. A.;ZAVALISHINA, A. I.;VORO+, TETRAHEDRON, 1981, 37, N 18, 3183-3194
    作者:NIFANTIEV, E. E.、SOROKINA, S. F.、BORISENKO, A. A.、ZAVALISHINA, A. I.、VORO+
    DOI:——
    日期:——
查看更多

表征谱图

  • 氢谱
    1HNMR
  • 质谱
    MS
  • 碳谱
    13CNMR
  • 红外
    IR
  • 拉曼
    Raman
查看更多图谱数据,请前往“摩熵化学”平台
查看更多图谱数据,请前往“摩熵化学”平台
cnmr
查看更多图谱数据,请前往“摩熵化学”平台
查看更多图谱数据,请前往“摩熵化学”平台
  • 峰位数据
  • 峰位匹配
  • 表征信息
Shift(ppm)
Intensity
查看更多图谱数据,请前往“摩熵化学”平台
Assign
Shift(ppm)
查看更多图谱数据,请前往“摩熵化学”平台
测试频率
样品用量
溶剂
溶剂用量
查看更多图谱数据,请前往“摩熵化学”平台

同类化合物

曲磷胺 曲磷胺 异环磷酰胺杂质F 异环磷酰胺 [(2-羟基-2-氧代-1,4,2-氧氮杂磷杂环己烷-4-基)甲基]膦酸 4-过氧化氢异环磷酰胺 4-氧代异环磷酰胺 4-乙基-7-甲基-7-氮杂-2,6-二氧杂-1-磷杂双环[2.2.2]辛烷1-硫化物 2’-氧代异环磷酰胺 2-[2-氯乙基-[3-(2-氯乙基)-2-氧代-1-氧杂-3-氮杂-2-磷杂环己-2-基]氨基]乙基甲烷磺酸酯 2,3,4,6,7,8-六氢-[1,3,2]氧氮杂膦咛并[2,3-b][1,3,2]氧氮杂膦咛 (2-氯-乙基)-[(R)-3-(2-氯-乙基)-2-氧代-2lambda5-[1,3,2]氧氮杂磷杂环己烷-2-基]-胺 (2R*,4aS*,8aR*)-1-methyl-2-phenyl-1,4,4a,5,6,7,8,8a-octahydro-2H-3,1,2-benzoxazaphosphinine 2-oxide (2S*,4aS*,8aR*)-2-phenyl-1,4,4a,5,6,7,8,8a-octahydro-2H-3,1,2-benzoxazaphosphinine 2-oxide (2R*,4aS*,8aS*)-1-methyl-2-phenyl-1,4,4a,5,6,7,8,8a-octahydro-2H-3,1,2-benzoxazaphosphinine 2-oxide (2S*,4aS*,8aS*)-2-phenyl-1,4,4a,5,6,7,8,8a-octahydro-2H-3,1,2-benzoxazaphosphinine 2-oxide (S,S)-2-oxo-2-propionyl-1,3,2-oxaphosphorinane 2-(Dimethylamino)-3-phenyl-1,3,2-oxazaphosphorinane 2-(1,1,1,3,3,3-Hexafluoroisopropoxy)-3,5,5-trimethyl-1,3,2-oxazaphosphorinane cis-2-(1,1,1,3,3,3-Hexafluoroisopropoxy)-3-methyl-5-tert-butyl-1,3,2-oxazaphosphorinane 2-(1,1,1,3,3,3-Hexafluoroisopropoxy)-3-methyl-1,3,2-oxazaphosphorinane 2-(1,1,1,3,3,3-Hexafluoroisopropoxy)-3-phenyl-1,3,2-oxazaphosphorinane 3,3,5,5-tetramethyl-2-oxido-2-oxo-1,4,2-oxaazaphosphorinane 2-(2-chloroethylamino)-3-(1-methyl-2-chloroethyl)tetrahydro-2H-1,3,2-oxazaphosphorine 2-oxide 4-ethyl-2-hydroxy-2-oxo-tetrahydro-4H-1,4,2-oxazaphosphorine geranyloxyifosfamide 4-methoxy-ifosfamide (2-chloroethyl)-[3-(2-chloroethyl)-2-oxo-4-pentyloxy-2λ5-[1,3,2]oxazaphosphinan-2-yl]amine 3-ethyl-2-hydroxy-2-oxo-1,4,2-oxazaphosphorinane Methyl-[3-(3-methyl-[1,3,2]oxazaphosphinan-2-yloxy)-propyl]-amine 2-Oxo-3-(propan-2-yl)-1,3,2-oxazaphosphinan-2-ium 3-(2-Chloroethyl)-2-(2-chloroethyl)amino-4-hydroxytetrahydro-2H-1,3,2-oxazaphosphorine 3-(2-Chloroethyl)-2-(1-ethyl-2-mesyloxyethylamino)-tetrahydro-2H-1,3,2-oxazaphosphorin-2-oxide 2H-1,3,2-Oxazaphosphorine, 2-fluorotetrahydro-3,5-dimethyl-, 2-oxide 2H-1,3,2-Oxazaphosphorine, 2-fluorotetrahydro-3,4-dimethyl-, 2-oxide (3-Isopropyl-2-oxo-2λ5-[1,3,2]oxazaphosphinan-2-yl)-acetic acid methyl ester cis-2-mesityl-2-oxo-3-phenyl-5-tert-butyl-1,3,2λ5-oxazaphosphorinane trans-2-mesityl-2-oxo-3-phenyl-5-tert-butyl-1,3,2λ5-oxazaphosphorinane (2S,6S)-2-Benzyl-3-(1,1-diethyl-propyl)-6-methyl-[1,3,2]oxazaphosphinane 2-oxide (2R,6S)-2-Benzyl-3-(1,1-diethyl-propyl)-6-methyl-[1,3,2]oxazaphosphinane 2-oxide (2S,6S)-2-((E)-2-Allyloxy-but-2-enyl)-3-tert-butyl-6-methyl-[1,3,2]oxazaphosphinane 2-oxide (2R,6S)-2-((E)-2-Allyloxy-but-2-enyl)-3-tert-butyl-6-methyl-[1,3,2]oxazaphosphinane 2-oxide (S)-(2l,6l)-2-(methoxymethyl)-6-methyl-3-(1-methylethyl)-1,3,2-oxazaphosphorinane 2-sulfide (S)-1-((2S,6S)-3-tert-Butyl-6-methyl-2-oxo-2λ5-[1,3,2]oxazaphosphinan-2-yl)-3-methyl-hex-5-en-2-one 2-methoxy-1,3,2-oxazaphosphinane 3-(2-Chloroethyl-2-<(2-chloroethyl)-(3-mesyloxytrimethylen)-amino>-tetrahydro-2H-1,3,2-oxazaphosphorin-2-oxide 2-chloro-3-[(S)-α-methylbenzyl]tetrahydro-2H-1,3,2-oxazaphosphorine 2-oxide (S)-(2u,6l)-3-(1,1-Diethylpropyl)-6-methyl-2-(2-propenyl)-1,3,2-oxazaphosphorinane 2-oxide 3-(2-chloro-ethyl)-2-(2-hydroxy-ethylamino)-2-oxo-2λ5-[1,3,2]oxazaphosphinan-4-one isopropyl-[3-(3-isopropyl-[1,3,2]oxazaphosphinan-2-yloxy)-propyl]-amine